AR063384A1 - Agentes terapeuticos a base de peptidos derivados de toxinas - Google Patents

Agentes terapeuticos a base de peptidos derivados de toxinas

Info

Publication number
AR063384A1
AR063384A1 ARP070104718A ARP070104718A AR063384A1 AR 063384 A1 AR063384 A1 AR 063384A1 AR P070104718 A ARP070104718 A AR P070104718A AR P070104718 A ARP070104718 A AR P070104718A AR 063384 A1 AR063384 A1 AR 063384A1
Authority
AR
Argentina
Prior art keywords
independently
revealed
composition
life
peptide
Prior art date
Application number
ARP070104718A
Other languages
English (en)
Inventor
Colin Victor Gegg Jr
Leslie Phillip Miranda
Beverly S Adler
Kenneth William Walker
Shaw-Fen Sylvia Hu
John K Sullivan
Joseph Mcgivern
Hung Q Nguyen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR063384A1 publication Critical patent/AR063384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Insects & Arthropods (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se revela una composicion de materia que tiene la siguiente formula (1): (X1)a-(F1)d-(X2)b-(F2)e-(X3)c y sus multímeros, donde F1 y F2 son fracciones que prolongan la semivida, y d y e son, cada uno en forma independiente, 0 o 1, siempre que al menos uno de d y e sea 1; X1, X2 y X3 son, cada uno en forma independiente, -(L)f-P-(L)g-, y f y g son, cada uno en forma independiente, 0 o 1; P es un péptido derivado de toxinas de no más de 80 residuos de aminoácidos, aproximadamente, que comprende al menos dos enlaces di-sulfuro intrapeptídicos, y al menos un P es un análogo del péptido OSK1; L es un enlazador optativo; y a, b y c son, cada uno en forma independiente, 0 o 1, siempre que al menos uno de a, b y c sea 1. La ligadura con la o las fracciones que prolongan la semivida aumenta la semivida in vivo del péptido derivado de toxinas, que de otra manera se degradaría rápidamente. Una composicion farmacéutica comprende la composicion y un portador farmacéuticamente aceptable. También se revelan ADN que codifican la composicion de materia novedosa, un vector de expresion que comprende el ADN y células hospedantes que comprenden el vector de expresion. También se revelan los métodos para tratar un trastorno autoinmune, tal como esclerosis multiple, diabetes tipo 1, psoriasis, enfermedad inflamatoria intestinal, dermatitis por contacto, artritis reumatoidea, artritis psoriásica, asma, alergia, restenosis, esclerosis sistémica, fibrosis, esclerodermia, glomerulonefritis, síndrome de Sjogren, resorcion osea inflamatoria, rechazo en transplante, enfermedad de injerto frente a anfitrion y lupus, pero sin limitarse exclusivamente a estos; como así también para prevenir o mitigar la recurrencia de un síntoma de esclerosis multiple.
ARP070104718A 2006-10-25 2007-10-25 Agentes terapeuticos a base de peptidos derivados de toxinas AR063384A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85467406P 2006-10-25 2006-10-25
US99537007P 2007-09-25 2007-09-25

Publications (1)

Publication Number Publication Date
AR063384A1 true AR063384A1 (es) 2009-01-28

Family

ID=39636515

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104718A AR063384A1 (es) 2006-10-25 2007-10-25 Agentes terapeuticos a base de peptidos derivados de toxinas

Country Status (8)

Country Link
US (6) US7910102B2 (es)
EP (1) EP2081602A2 (es)
AR (1) AR063384A1 (es)
AU (1) AU2007343796A1 (es)
CA (1) CA2667678A1 (es)
PE (1) PE20081140A1 (es)
TW (1) TW200833840A (es)
WO (1) WO2008088422A2 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
DE602006020710D1 (de) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
AR063384A1 (es) * 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8598311B2 (en) * 2007-11-21 2013-12-03 The University Of The Sciences In Philadelphia Complexation of fatty acid-conjugated molecules with albumin
EP2229473A4 (en) * 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
ES2345527B1 (es) 2008-10-08 2011-09-08 Hospital Clinic I Provincial De Barcelona Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima.
EP3385279B1 (en) * 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2011032233A1 (en) 2009-09-21 2011-03-24 The University Of Queensland Novel omega conotoxin peptides
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
US20110144028A1 (en) * 2009-12-11 2011-06-16 Vinod Sharma Modulating cellular electrophysiology
HRP20171291T1 (hr) 2010-02-04 2017-10-20 Morphotek, Inc. Polipeptidi i konjugati klorotoksina i njihove uporabe
EP2563406A4 (en) 2010-04-30 2013-11-13 Alexion Pharma Internat Sarl METHOD, COMPOSITIONS AND KITS FOR TREATING MATRIX MINERALIZATION DISORDERS
CN103097403B (zh) * 2010-05-11 2017-04-19 弗雷德哈钦森癌症研究中心 氯毒素变体、缀合物及其使用方法
JP2013535692A (ja) 2010-08-10 2013-09-12 アムジエン・インコーポレーテツド 標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2658979B1 (en) * 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
SG11201401605QA (en) * 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
EP3973981A1 (en) 2012-05-18 2022-03-30 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9283241B2 (en) * 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
CA2880929A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
CA2913127A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
NZ709913A (en) * 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
WO2014160037A2 (en) 2013-03-14 2014-10-02 The Regents Of The University Of California Activatable membrane-interacting peptides and methods of use
WO2015001015A1 (en) * 2013-07-04 2015-01-08 Universitat De Barcelona Actively transported and protease-resistant peptides as bbb shuttles and shuttle-cargo constructs
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
ES2841173T3 (es) 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
AU2013404615B2 (en) * 2013-10-28 2018-05-17 Baylor College Of Medicine Novel scorpion toxin analogue and method for treating autoimmune diseases
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
GB201408135D0 (en) * 2014-05-08 2014-06-25 Conogenetix Biosciences Gmbh Kv1.3 potassium channel antagonists
EP3155002B1 (en) 2014-06-10 2019-11-27 Amgen Inc. Apelin polypeptides
US10328149B2 (en) 2014-06-13 2019-06-25 Tenboron Oy Conjugates comprising an anti-EGFR1 antibody
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
AU2015303825B2 (en) 2014-08-15 2021-01-14 Baylor College Of Medicine Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2972871A1 (en) * 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
TW201708249A (zh) 2015-04-02 2017-03-01 健生生物科技公司 原毒素－ｉｉ變體及使用方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CA3025310A1 (en) 2016-05-23 2017-11-30 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
IL265236B2 (en) 2016-09-29 2023-11-01 Aebi Ltd Multipurpose medical buildings and their uses
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110352197B (zh) 2016-12-09 2024-02-02 Uab研究基金会 嵌合氯毒素受体
WO2018119001A1 (en) * 2016-12-19 2018-06-28 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
KR102624254B1 (ko) 2017-01-06 2024-01-12 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
MX2019011508A (es) 2017-03-31 2019-11-01 Alexion Pharma Inc Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes.
US11331393B2 (en) 2017-06-15 2022-05-17 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
KR20210077724A (ko) 2018-10-16 2021-06-25 글로 파마, 인크. 니코틴성 아세틸콜린 수용체 펩티드 길항제 코노톡신 조성물 및 관련된 방법
CN109106943B (zh) * 2018-11-05 2021-04-20 中国科学院上海有机化学研究所 抗癫痫的毒素Martentoxin及其应用
JP2020080784A (ja) * 2018-11-29 2020-06-04 シスメックス株式会社 融合ポリペプチド、融合ポリペプチドの製造方法、及び融合ポリペプチドをコードするｄｎａ
CA3155089A1 (en) * 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers
MX2022007114A (es) 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
MX2023002673A (es) 2020-09-04 2023-05-12 Alexion Pharma Inc Métodos para el tratamiento de trastornos de mineralización ósea.
WO2022066767A2 (en) 2020-09-23 2022-03-31 Aldevron, Llc Potent and selective inhibitors of nav1.7
EP4291224A4 (en) 2021-02-12 2025-01-01 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
BR112023019022A2 (pt) 2021-03-23 2023-10-17 Zealand Pharma As Bloqueadores de kv1.3
CN113930462A (zh) * 2021-10-19 2022-01-14 江南大学 高丝氨酸内酯信号分子促进碳链延长微生物合成己酸的方法
CN115259378B (zh) * 2022-08-25 2024-04-12 华南农业大学 一种富集污水处理系统中氨氧化古菌的方法
EP4604984A1 (en) 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4083368A (en) 1976-09-01 1978-04-11 Freezer Winthrop J Inhaler
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4686283A (en) 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JPH0669959B2 (ja) 1985-09-26 1994-09-07 東燃株式会社 コレラ毒素類を活性成分とする免疫抑制剤
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH01502909A (ja) 1987-02-24 1989-10-05 ゾーマ・コーポレーション 免疫毒素による人間の治療における免疫抑制
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
AU633020B2 (en) 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences
US4925677A (en) 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
CN1071436A (zh) 1988-12-19 1993-04-28 约翰·J·曼斯特 木质素-丙烯酰胺-苯乙烯接枝共聚物，制法及应用
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5397702A (en) 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US4906159A (en) * 1989-03-22 1990-03-06 Caterpillar Industrial Inc. Freely positionable load carrying attachment for an automatic guided vehicle
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
IL98932A0 (en) 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
JPH0640945A (ja) * 1992-07-23 1994-02-15 Kureha Chem Ind Co Ltd Ｆｃフラグメント結合抗腫瘍剤
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5494895A (en) 1993-07-22 1996-02-27 Merck & Co., Inc. Scorpion peptide margatoxin with immunosuppressant activity
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2184002A1 (en) 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2717688B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CN1170360A (zh) 1994-12-21 1998-01-14 瑟垃技术有限公司 具有粘性贴面和剥离密封圆片的经皮输送系统
WO1996019198A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7288254B2 (en) * 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US6632928B1 (en) 1997-03-05 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5763478A (en) 1996-10-16 1998-06-09 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
WO1998023639A2 (en) 1996-11-27 1998-06-04 University Of Florida ShK TOXIN COMPOSITIONS AND METHODS OF USE
CA2247328C (en) 1996-12-26 2007-01-30 Suntory Limited Neuropeptides originating in scorpion
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
SG129211A1 (en) 1997-11-06 2007-02-26 Univ Singapore Therapeutic molecules
US6551821B1 (en) 1997-12-23 2003-04-22 The Trustees Of Columbia University In The City Of New York Brain cyclic nucleotide gated ion channel and uses thereof
US6703485B2 (en) 1997-12-23 2004-03-09 The Trustees Of Columbia University In The City Of New York Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
JP3515072B2 (ja) 1998-01-23 2004-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成長因子模倣物質、成長因子および阻害因子の同定に用いられる方法および組成物
JP3530004B2 (ja) 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US6022952A (en) * 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1132479B1 (en) 1998-11-20 2009-04-22 Fuso Pharmaceutical Industries Ltd. Protein expression vector and utilization thereof
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
JP2002533378A (ja) 1998-12-23 2002-10-08 アムジエン・インコーポレーテツド タンパク質の徐放用ポリオール／油懸濁液
CA2368068A1 (en) 1999-03-18 2000-09-21 Steven M. Ruben 27 human secreted proteins
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1623994A3 (en) 1999-05-17 2008-07-16 ConjuChem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6768002B1 (en) 1999-06-22 2004-07-27 E. I. Du Pont De Nemours And Company Scorpion toxins
WO2000078958A2 (en) 1999-06-22 2000-12-28 E.I. Du Pont De Nemours And Company Scorpion toxins from buthotus judaicus
US6096891A (en) 1999-12-09 2000-08-01 Air Products And Chemicals, Inc. Process for the production of cyclic N,N'-dialkylureas
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
SE0000935D0 (sv) 2000-03-21 2000-03-21 Astrazeneca Ab An inhalation device
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US6946134B1 (en) * 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU5943201A (en) 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
DE60128216T2 (de) 2000-05-12 2008-01-10 Amgen Inc., Thousand Oaks Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
EP1177806A1 (en) 2000-08-04 2002-02-06 The Technology Partnership Public Limited Company Dry powder inhaler
AU2002212201A1 (en) 2000-09-04 2002-03-22 Cellpep S.A. Maurotoxin, pi1 and hstx1 derivatives
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7055600B2 (en) 2001-04-24 2006-06-06 Shell Oil Company In situ thermal recovery from a relatively permeable formation with controlled production rate
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6861405B2 (en) 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20040152769A1 (en) 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PT1641483E (pt) 2003-06-12 2008-04-29 Lilly Co Eli Proteínas de fusão
WO2005047337A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
JP5118969B2 (ja) * 2004-10-07 2013-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
AR063384A1 (es) * 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas

Also Published As

Publication number Publication date
US20090281028A1 (en) 2009-11-12
US7834164B2 (en) 2010-11-16
US20090297520A1 (en) 2009-12-03
WO2008088422A2 (en) 2008-07-24
EP2081602A2 (en) 2009-07-29
TW200833840A (en) 2008-08-16
PE20081140A1 (es) 2008-09-22
US20090299044A1 (en) 2009-12-03
AU2007343796A1 (en) 2008-07-24
US20090318341A1 (en) 2009-12-24
US7825093B2 (en) 2010-11-02
US8043829B2 (en) 2011-10-25
US7820623B2 (en) 2010-10-26
WO2008088422A3 (en) 2009-02-19
US20090291885A1 (en) 2009-11-26
US7803769B2 (en) 2010-09-28
US20090305399A1 (en) 2009-12-10
US7910102B2 (en) 2011-03-22
CA2667678A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
AR053234A1 (es) Agentes terapeuticos a base de peptidos de toxinas
TW200833840A (en) Toxin peptide therapeutic agents
DOP2009000194A (es) Glucagon/co-agonistas receptores de glp-1
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
NZ503720A (en) Nucleotide sequences encoding ApoA-I agonists and their use in pharmaceutical compositions to treat dyslipidemic disorders such as cardiovascular disease
ES2126743T3 (es) Alfa-amilasa oxidativamente estable.
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
AR051071A1 (es) Antagonismo de la actividad del receptor de interleuquina-21
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
ATE432291T1 (de) Kdr-peptide und diese enthaltende impfstoffe
PA8830501A1 (es) Co-agonistas del receptor de glucagon/glp-1
MX336623B (es) Peptidos penetradores de las celulas y usos de los mismos.
EA200870237A1 (ru) Последовательности пептидов и композиции
CO5570710A2 (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico
TNSN07396A1 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AR065075A1 (es) Vectores para la expresion multiple de genes
JP2010222379A5 (es)
AR006813A1 (es) Peptidos consistentes en 16 a 55 residuos de aminoacido, composicion farmaceutica que comprende a por lo menos uno de dichos peptidos, metodo dediagnostico para la deteccion de celulas t auto-reactivas activadas que utiliza a por lo menos uno de tales peptidos y equipo para pruebas utilizado en dicho
JP2009536182A5 (es)
DE602005025141D1 (de) In Zellen eindringende Peptide als Träger für Moleküle
Nguyen et al. Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction

Legal Events

Date Code Title Description
FA Abandonment or withdrawal